Johnson & Johnson is in touch with the central government to start clinical trial of its much awaited single-dose COVID-19 vaccine in India, the company confirmed on Friday.
"We are in discussions with the (government) with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals," a local J&J representative said.
The news comes as some parts of India face a shortage of vaccine supplies just as the country of 1.3 billion battles a second wave of COVID-19 infections. India's government, however, has said there is no shortage of shots.
Earlier on Friday, it was reported that that J&J had sent a letter to India's Central Drugs Standard Control Organisation (CDSCO) saying it would "very shortly apply for permission to conduct clinical bridging trials in India".